NCT01939275View on ClinicalTrials.gov

64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

March 30, 2019

Study Completion Date

August 5, 2024

Conditions
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Gastric CancerStage IA Gastric CancerStage IB Gastric CancerStage IIA Gastric CancerStage IIB Gastric CancerStage IIIA Gastric CancerStage IIIB Gastric CancerStage IIIC Gastric CancerStage IV Gastric Cancer
Interventions
RADIATION

copper Cu 64-DOTA-trastuzumab

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

DEVICE

positron emission tomography

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

Computed Tomography

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER

NCT01939275 - 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer | Biotech Hunter | Biotech Hunter